Pauci-immune glomerulonephritis with ANCA
MONDO:0019988Pauci-immune glomerulonephritis (GN) with antineutrophil cytoplasmic antibodies (ANCA) is a form of rapidly progressive GN comprising about 90% of pauci-immune glomerulonephritis, and associated with the presence of circulating ANCA (mostly directed against proteinase-3 (PR3) and myeloperoxidase (MPO)). Patients usually present with hematuria and rapidly declining renal function, often leading to dialysis within weeks without treatment. Cutaneous, pulmonary, musculoskeletal and nervous involvement may be observed in case of systemic disease, and the correlation between ANCA titer and disease activity has been demonstrated.
Also known as: pauci-immune glomerulonephritis with antineutrophil cytoplasmic antibody
7 clinical trials for this condition and its sub-types, 4 tagged with Pauci-immune glomerulonephritis with ANCA itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Experimental cell therapy targets kidney disease
Disease control Not yet recruitingThis early-phase trial is testing a new cell therapy called GT719 for several immune-mediated kidney diseases, including IgA nephropathy and membranous nephropathy. The therapy uses specially engineered immune cells to target and potentially control the disease. The study will en…
Early phase 1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug STR-P004 aims to tame immune attacks on kidneys
Disease control Not yet recruitingThis early study tests a new drug called STR-P004 in 9 adults with immune-mediated kidney diseases. The goal is to see if the drug is safe and how the body processes it. Participants receive up to 8 infusions over 28 days, with possible dose increases. This is not a cure; it aims…
Sponsor: Starna Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC